Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Adjuvant Chemotherapy in Patients With Early-Stage Non–Small Cell Lung Cancer

Adjuvant Chemotherapy in Patients With Early-Stage Non–Small Cell Lung Cancer Letters submitted work. Dr Bal reported receiving grants from Amyloidosis Foundation significant difference between the study by Premkumar et al outside the submitted work. Dr Costa reported receiving grants and personal and ours is the length of follow-up. Whereas the former used fees from Janssen during the submitted work and grants and personal fees from the original MAIA publication with a median follow-up of 28 Amgen and personal fees from Bristol Myers Squibb and Sanofi outside the months, we used the more recent update of this trial submitted work. (NCT02252172) with a median follow-up of 36 months. It 1. Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic appears that the progression-free survival benefit in the review and meta-analysis. JAMA Oncol. 2020;6(11):1-8. doi:10.1001/jamaoncol. daratumumab arm deepened with extended follow-up, leading 2020.4338 to lower hazard ratio and reaching our preestablished threshold 2. Mohyuddin GR, Sigle M, Chandrasekar VT, et al. Impact of anti-CD38 therapy of statistical significance. in multiple myeloma with high-risk cytogenetics: systematic review and In their comments, Mohyuddin et al question the benefit meta-analysis. Leuk Lymphoma. 2020;61(10):2519-2522. doi:10.1080/ 10428194.2020.1772475 of daratumumab in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Adjuvant Chemotherapy in Patients With Early-Stage Non–Small Cell Lung Cancer

JAMA Oncology , Volume 7 (4) – Apr 25, 2021

Loading next page...
 
/lp/american-medical-association/adjuvant-chemotherapy-in-patients-with-early-stage-non-small-cell-lung-lWC7YFVjTu

References (5)

Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.8186
Publisher site
See Article on Publisher Site

Abstract

Letters submitted work. Dr Bal reported receiving grants from Amyloidosis Foundation significant difference between the study by Premkumar et al outside the submitted work. Dr Costa reported receiving grants and personal and ours is the length of follow-up. Whereas the former used fees from Janssen during the submitted work and grants and personal fees from the original MAIA publication with a median follow-up of 28 Amgen and personal fees from Bristol Myers Squibb and Sanofi outside the months, we used the more recent update of this trial submitted work. (NCT02252172) with a median follow-up of 36 months. It 1. Giri S, Grimshaw A, Bal S, et al. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic appears that the progression-free survival benefit in the review and meta-analysis. JAMA Oncol. 2020;6(11):1-8. doi:10.1001/jamaoncol. daratumumab arm deepened with extended follow-up, leading 2020.4338 to lower hazard ratio and reaching our preestablished threshold 2. Mohyuddin GR, Sigle M, Chandrasekar VT, et al. Impact of anti-CD38 therapy of statistical significance. in multiple myeloma with high-risk cytogenetics: systematic review and In their comments, Mohyuddin et al question the benefit meta-analysis. Leuk Lymphoma. 2020;61(10):2519-2522. doi:10.1080/ 10428194.2020.1772475 of daratumumab in

Journal

JAMA OncologyAmerican Medical Association

Published: Apr 25, 2021

There are no references for this article.